Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 03, 2023 07:35 ET | Source: Windtree Therapeutics

Windtree Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., April 03, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular...
March 13, 2023 08:00 ET | Source: Windtree Therapeutics

Windtree Regains Compliance with Nasdaq

WARRINGTON, Pa., March 13, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
March 06, 2023 08:00 ET | Source: Windtree Therapeutics

Windtree Finds Cardiogenic Shock Has High Cost of US Patient Care and Plans Innovation with the Unique Profile of Istaroxime

US Hospital Claims Data Reveals Cardiogenic Shock Patients Have an Average Hospital Length of Stay of 19.6 Days Making Its Intensive Patient Care Cost Very High WARRINGTON, Pa., March 06, 2023 ...
February 28, 2023 08:00 ET | Source: Windtree Therapeutics

Windtree Announces Publication on its SERCA2a Activator Drug Candidate for Chronic and Acute Heart Failure

WARRINGTON, Pa., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage...
February 27, 2023 08:00 ET | Source: Windtree Therapeutics

Windtree Announces Istaroxime Scientific Abstract Has Been Accepted at the 2023 Technology and Heart Failure Therapeutics Conference

WARRINGTON, Pa., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
February 24, 2023 08:00 ET | Source: Windtree Therapeutics

Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark Office

WARRINGTON, Pa., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage...
February 23, 2023 12:00 ET | Source: Windtree Therapeutics

Windtree Therapeutics Announces Reverse Stock Split

WARRINGTON, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”), a biotechnology company focused on advancing multiple late-stage...
January 20, 2023 08:37 ET | Source: Windtree Therapeutics

Windtree Therapeutics to Raise $1.0 Million From the Exercise of Previously Issued Warrants

WARRINGTON, Pa., Jan. 20, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”) today announced it has entered into warrant inducement offer letters (the...
December 05, 2022 07:30 ET | Source: Windtree Therapeutics

Nasdaq Grants Windtree Therapeutics 180-day Extension to Regain Compliance

WARRINGTON, Pa., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage...
November 14, 2022 07:30 ET | Source: Windtree Therapeutics

Windtree Therapeutics Reports Third Quarter 2022 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular...